Speedel Group: Strings Attached? No Problem

Speedel Group sets itself apart from many in-licensing companies by offering partners a call-back option on development projects. This, plus its tight focus on renin inhibition and Big Pharma savvy management have allowed the group to build a pipeline. Critics say the model restricts Speedel's upside. But the success of its first project, Novartis' Phase III SPP100, and one of Europe's largest private financings of 2003 suggest the group has a strong chance of proving them wrong.

In 1998, one of Novartis AG 's top late-stage development prospects, the first-in-class Phase III renin inhibitor aliskiren, was an early-stage project that didn't quite make the grade. Novartis didn't want to commit significant resources to develop the anti-hypertensive; renin inhibitors, although scientifically interesting, had failed to live up to their early promise—indeed more than 30 years after the blood pressure regulating renin-angiotensin system (RAS) was first pharmacologically tweaked by inhibiting angiotensin-converting enzyme (ACE), no renin inhibitors have made it to the market. (See Sidebar: The Renin-Angiotensin System.)

But neither did the Big Pharma, fresh from its formation after the March 1996 merger of Sandoz and Ciba-Geigy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Global Vision

Turning Defense Into Attack: Snapshots Of A Changing Medtech Market And How To Respond

 
• By 

Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes, and keeping unmet needs and outcomes in the center of the target.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By 

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Unpacking The Impact Of Trump’s Tariffs On Drug Pricing And Production

 
• By 

Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.